振東製藥(300158.SZ)上半年淨利預增70%-90%
格隆匯7月13日丨振東製藥(300158.SZ)披露2021年半年度業績預吿,公司預計2021年1-6月實現歸屬於上市公司股東的淨利潤2.00億元-2.24億元,同比增長70%-90%。業績預增原因系:
1、報吿期內,朗迪鈣業務方面,市場逐步下沉第三終端,銷售保持增長;傳統中藥板塊,繼續深耕市場,加大學術支持,穩紮穩打,銷售業績穩步增長;達霏欣等潛力產品繼續發力,報吿期內有很好的增長。
2、報吿期內計入當期損益的非經常性損益對公司淨利潤的影響約為3000-3500萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.